- Home
- TECX vs LIEN Comparison
TECX vs LIEN Comparison
Compare TECX & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- LIEN
- Stock Information
- Founded
- TECX 2019
- LIEN 2021
- Country
- TECX United States
- LIEN United States
- Employees
- TECX N/A
- LIEN N/A
- Industry
- TECX
- LIEN
- Sector
- TECX
- LIEN
- Exchange
- TECX Nasdaq
- LIEN NYSE
- Market Cap
- TECX 647.7M
- LIEN 292.1M
- IPO Year
- TECX 2018
- LIEN 2022
- Fundamental
- Price
- TECX $45.69
- LIEN $12.56
- Analyst Decision
- TECX Strong Buy
- LIEN
- Analyst Count
- TECX 5
- LIEN 0
- Target Price
- TECX $72.25
- LIEN N/A
- AVG Volume (30 Days)
- TECX 94.6K
- LIEN 9.5K
- Earning Date
- TECX 02-24-2025
- LIEN 11-07-2024
- Dividend Yield
- TECX N/A
- LIEN 9.09%
- EPS Growth
- TECX N/A
- LIEN N/A
- EPS
- TECX N/A
- LIEN 0.67
- Revenue
- TECX N/A
- LIEN $12,681,914.00
- Revenue This Year
- TECX N/A
- LIEN N/A
- Revenue Next Year
- TECX N/A
- LIEN N/A
- P/E Ratio
- TECX N/A
- LIEN $17.97
- Revenue Growth
- TECX N/A
- LIEN 22.94
- 52 Week Low
- TECX $1.40
- LIEN $7.29
- 52 Week High
- TECX $53.41
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- TECX 47.61
- LIEN N/A
- Support Level
- TECX $42.83
- LIEN N/A
- Resistance Level
- TECX $51.76
- LIEN N/A
- Average True Range (ATR)
- TECX 3.58
- LIEN 0.00
- MACD
- TECX -0.42
- LIEN 0.00
- Stochastic Oscillator
- TECX 27.17
- LIEN 0.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.